特应性皮炎中的免疫、微生物和上皮相互作用。
Immunologic, microbial, and epithelial interactions in atopic dermatitis.
机构信息
The Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York.
Department of Pediatrics, National Jewish Health, Denver, Colorado.
出版信息
Ann Allergy Asthma Immunol. 2018 Jan;120(1):34-41. doi: 10.1016/j.anai.2017.09.055. Epub 2017 Nov 7.
Abstract
OBJECTIVE
To provide an overview of studies contributing to the understanding of immunologic, microbial, and epithelial interactions in atopic dermatitis.
DATA SOURCES
PubMed literature review (2000-2017) and meeting abstracts from recent international dermatology conferences.
STUDY SELECTIONS
Articles discussing primarily human disease.
RESULTS
Clinical studies showed that atopic dermatitis is a type 2 immune-centered disease with a systemic inflammatory component but with heterogeneous treatment responses. This suggests that other factors are likely involved in shaping the skin disease phenotype, including microbial dysbiosis and epidermal barrier dysfunction.
CONCLUSION
Recent clinical investigation has significantly expanded our knowledge on disease pathogenesis in atopic dermatitis, and current and future clinical trials will most likely further help to elucidate this complex, heterogeneous skin disease.
摘要
目的
综述有助于了解特应性皮炎中免疫、微生物和上皮相互作用的研究。
资料来源
PubMed 文献回顾（2000-2017 年）和最近国际皮肤病会议的会议摘要。
研究选择
主要讨论人类疾病的文章。
结果
临床研究表明，特应性皮炎是一种以 2 型免疫为中心的疾病，具有系统性炎症成分，但治疗反应存在异质性。这表明，其他因素可能参与塑造皮肤疾病表型，包括微生物失调和表皮屏障功能障碍。
结论
最近的临床研究显著扩展了我们对特应性皮炎发病机制的认识，目前和未来的临床试验很可能进一步有助于阐明这种复杂的、异质性的皮肤疾病。
相似文献
1
Immunologic, microbial, and epithelial interactions in atopic dermatitis.
Ann Allergy Asthma Immunol. 2018 Jan;120(1):34-41. doi: 10.1016/j.anai.2017.09.055. Epub 2017 Nov 7.
2
Effect of Staphylococcus aureus colonization and immune defects on the pathogenesis of atopic dermatitis.
Arch Microbiol. 2024 Sep 20;206(10):410. doi: 10.1007/s00203-024-04134-w.
3
The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis.
Nat Immunol. 2018 Dec;19(12):1286-1298. doi: 10.1038/s41590-018-0256-2. Epub 2018 Nov 16.
4
The Influence of Microbiome Dysbiosis and Bacterial Biofilms on Epidermal Barrier Function in Atopic Dermatitis-An Update.
Int J Mol Sci. 2021 Aug 5;22(16):8403. doi: 10.3390/ijms22168403.
5
On the surface: Skin microbial exposure contributes to allergic disease.
Ann Allergy Asthma Immunol. 2020 Dec;125(6):628-638. doi: 10.1016/j.anai.2020.08.025. Epub 2020 Aug 25.
6
The Microbiome and Atopic Dermatitis: A Review.
Am J Clin Dermatol. 2019 Dec;20(6):749-761. doi: 10.1007/s40257-019-00467-1.
7
Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends.
J Dermatol Sci. 2019 Aug;95(2):56-61. doi: 10.1016/j.jdermsci.2019.07.001. Epub 2019 Jul 5.
8
Skin Microbiome in Atopic Dermatitis.
Acta Derm Venereol. 2020 Jun 9;100(12):adv00164. doi: 10.2340/00015555-3514.
9
The role of filaggrin in atopic dermatitis and allergic disease.
Ann Allergy Asthma Immunol. 2020 Jan;124(1):36-43. doi: 10.1016/j.anai.2019.10.008. Epub 2019 Oct 14.
10
Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions.
Ann Allergy Asthma Immunol. 2020 Nov;125(5):517-527. doi: 10.1016/j.anai.2020.05.016. Epub 2020 May 23.
引用本文的文献
1
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb). 2025 Jul 15. doi: 10.1007/s13555-025-01481-4.
2
Identification and analysis of cuproptosis associated molecular clusters and immunological profiles in atopic dermatitis.
Front Immunol. 2025 Jun 27;16:1545457. doi: 10.3389/fimmu.2025.1545457. eCollection 2025.
3
Decoding Cuproptosis-Sphingolipid-Immune Crosstalk in Atopic Dermatitis: A Multi-Omics Network Analysis.
Biomedicines. 2025 May 31;13(6):1349. doi: 10.3390/biomedicines13061349.
4
Fecal microbiota transplantation in allergic diseases.
World J Methodol. 2025 Jun 20;15(2):101430. doi: 10.5662/wjm.v15.i2.101430.
5
Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors.
J Clin Med. 2025 Feb 15;14(4):1291. doi: 10.3390/jcm14041291.
6
The AhR-Ovol1-Id1 regulatory axis in keratinocytes promotes epidermal and immune homeostasis in atopic dermatitis-like skin inflammation.
Cell Mol Immunol. 2025 Mar;22(3):300-315. doi: 10.1038/s41423-025-01264-z. Epub 2025 Feb 13.
7
Genomic epidemiology and phenotypic characterization of Staphylococcus aureus isolated from atopic dermatitis patients in South China.
Sci Rep. 2025 Feb 8;15(1):4773. doi: 10.1038/s41598-025-87317-9.
8
The primary mechanisms underlying atopic dermatitis.
Tunis Med. 2025 Jan 5;103(1):65-72. doi: 10.62438/tunismed.v103i1.5220.
9
The evaluation of the serum levels of vitamin D and interleukin-33 in children with atopic dermatitis and its association with diseases severity.
Arch Dermatol Res. 2025 Jan 7;317(1):182. doi: 10.1007/s00403-024-03709-3.
10
The Beneficial Roles of Seaweed in Atopic Dermatitis.
Mar Drugs. 2024 Dec 17;22(12):566. doi: 10.3390/md22120566.
本文引用的文献
1
The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.
Sci Rep. 2017 Aug 18;7(1):8707. doi: 10.1038/s41598-017-09207-z.
2
Identification of unique proteomic signatures in allergic and non-allergic skin disease.
Clin Exp Allergy. 2017 Nov;47(11):1456-1467. doi: 10.1111/cea.12979. Epub 2017 Aug 11.
3
and strain diversity underlying pediatric atopic dermatitis.
Sci Transl Med. 2017 Jul 5;9(397). doi: 10.1126/scitranslmed.aal4651.
4
Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.
Allergy. 2018 Jan;73(1):29-36. doi: 10.1111/all.13239. Epub 2017 Jul 20.
5
Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march.
J Allergy Clin Immunol. 2017 Jun;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004.
6
Public Health Burden and Epidemiology of Atopic Dermatitis.
Dermatol Clin. 2017 Jul;35(3):283-289. doi: 10.1016/j.det.2017.02.002. Epub 2017 Apr 22.
7
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Drugs Today (Barc). 2017 Apr;53(4):239-245. doi: 10.1358/dot.2017.53.4.2604174.
8
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
9
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.
J Allergy Clin Immunol. 2017 Apr;139(4S):S65-S76. doi: 10.1016/j.jaci.2017.01.011.
10
Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study.
Br J Dermatol. 2017 Aug;177(2):419-427. doi: 10.1111/bjd.15493. Epub 2017 Jun 27.
Zotero 插件